Enzo Biochem Q4 Revenues Up 4 Percent on Increased Lab Services Revenues | GenomeWeb

NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market on Thursday that its fourth quarter revenues rose 4 percent year over year, thanks to an increase in revenues from its clinical laboratory services business.

For the three-month period ended July 31, the molecular diagnostics company reported revenues of $26.6 million, up from $25.7 million a year earlier.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.